Key Highlights

  • Cash, cash equivalents and investments were USD 503.5 million on September 30, 2026, which the company believes is sufficient to fund projected operating expenses and Capital Expenditure into 2029.
  • Net loss for the third quarter of 2026 was USD 26.5 million, or USD 0.51 per share, against USD 59.1 million, or USD 10.05, a year earlier.
  • Research and development expense was USD 17.5 million, compared with USD 9 thousand a year earlier, while general and administrative expense rose to USD 12.6 million from USD 0.5 million.
  • The August 2026 IPO sold 24,437,500 shares at USD 18.00 each for gross proceeds of USD 439.9 million and net proceeds of about USD 404.4 million.

First Quarterly Report After the IPO Shows a USD 503.5 Million Balance

Braveheart Bio (NASDAQ:BRVE) filed its quarterly report on November 10, 2026, covering the period ended September 30, 2026, its first since an initial public offering that closed in August. The IPO sold 24,437,500 shares, including the full underwriter option, at USD 18.00, raising USD 439.9 million gross and about USD 404.4 million net after fees and costs. The company also completed a 1-for-4.38 Reverse Stock Split on July 29, 2026. It reported USD 503.5 million in cash, cash equivalents and investments, and says this should last into 2029 on its current operating plan, though it warns that assumptions may prove wrong and capital could run out sooner.

Why the Loss Narrowed From USD 59.1 Million to USD 26.5 Million

The third quarter net loss was USD 26.5 million (GAAP), or USD 0.51 per share, against USD 59.1 million, or USD 10.05. The prior year quarter was dominated by USD 58.8 million of in-process Research and Development tied to the license of BHB-1893 from Hengrui, so the comparison is not like for like. This year, clinical trial expenses were USD 7.2 million, Manufacturing USD 2.2 million and license milestones USD 1.0 million. General and administrative expense reached USD 12.6 million on public company and Stock Compensation costs. Interest income rose to USD 3.7 million. Nine-month net loss was USD 55.8 million, and the accumulated Deficit was USD 122.4 million.

BHB-1893 Data and the Phase 3 Calendar

The company is a clinical-stage biopharmaceutical Business developing BHB-1893, an oral cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy. On November 6, 2026 it presented 52-week open-label extension data from a Phase 2 trial by Hengrui in 42 patients, and 79% reached a gradient below 30 mmHg at Week 52. No new cases of ejection fraction below 50% had been seen as of the data cutoff. The Phase 3 LIONHEART-HCM trial is enrolling, with an interim analysis expected in the second half of 2027. Two further Phase 3 trials are planned for the first half of 2027. It has no approved product and no revenue, and results may change in later trials.

Where Things Stand

Cash runs into 2029 under the company's current operating plan, but that is an estimate rather than a guarantee. Braveheart Bio (NASDAQ:BRVE) holds USD 503.5 million and reported a quarterly net loss of USD 26.5 million, yet expenses are set to climb as Phase 3 programs expand and it builds commercial capabilities. Dilution from future financing remains possible if plans change. Next markers are Phase 3 trial starts in the first half of 2027, 52-week data from the non-obstructive Phase 2 extension, and the interim analysis of LIONHEART-HCM in the second half of 2027.